• Publications
  • Influence
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PURPOSE To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma. PATIENTS AND METHODS Peripheral neuropathyExpand
  • 547
  • 28
  • PDF
Distal acquired demyelinating symmetric neuropathy
Objective: To characterize an acquired, symmetric, demyelinating neuropathic variant with distal sensory or sensorimotor features. Background: Classic chronic inflammatory demyelinatingExpand
  • 245
  • 21
Correction for Eisenberg et al., Distinctive patterns of microRNA expression in primary muscular disorders
The primary muscle disorders are a diverse group of diseases caused by various defective structural proteins, abnormal signaling molecules, enzymes and proteins involved in posttranslationalExpand
  • 257
  • 20
  • PDF
Regional Energy Demand Responses To Climate Change: Methodology And Application To The Commonwealth Of Massachusetts
Climate is a major determinant of energy demand. Changes in climate may alter energy demand as well as energy demand patterns. This study investigates the implications of climate change for energyExpand
  • 202
  • 16
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.
Dermatomyositis has been modeled as an autoimmune disease largely mediated by the adaptive immune system, including a local humorally mediated response with B and T helper cell muscle infiltration,Expand
  • 249
  • 15
119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands
Department of Neurology, University Medical Center, Heidelberg laan 100, Utrecht, CX 3584, The Netherlands Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,Expand
  • 582
  • 14
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
The frequency, characteristics and reversibility of bortezomib‐associated peripheral neuropathy were evaluated in the phase III APEX (Assessment of Proteasome Inhibition for Extending Remissions)Expand
  • 263
  • 12
Inclusion body myositis
Opinion statementInclusion body myositis (IBM) is usually refractory to immunosuppressive therapy; however, a few reports suggest that a minority of patients with IBM may have a partial, transientExpand
  • 253
  • 12
The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.
The non-dystrophic myotonias are an important group of skeletal muscle channelopathies electrophysiologically characterized by altered membrane excitability. Many distinct clinical phenotypes are nowExpand
  • 153
  • 11
  • PDF
Clinical spectrum of chronic acquired demyelinating polyneuropathies
A number of presentations of chronic demyelinating polyneuropathy have been identified, each distinguished by its phenotypic pattern. In addition to classic chronic inflammatory demyelinatingExpand
  • 372
  • 10